Beyond Air, Inc.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 13, 2026
XAIR$2.52+10.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)
| For the Nine Months Ended | ||||
|---|---|---|---|---|
| December 31, | ||||
| 2025 · 2024 | ||||
| Cash flows from operating activities | ||||
| Net loss | $(23,966) | $(40,416) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||
| Depreciation | 2,269 | 2,209 | ||
| Amortization of licensed right to use technology | 153 | 154 | ||
| Stock-based compensation | 4,855 | 8,988 | ||
| Amortization of debt discount and accretion of debt issuance costs | 345 | 897 | ||
| Change in fair value of warrant liability | (36) | (219) | ||
| Change in fair value of derivative liability | (483) | (1,314) | ||
| Amortization of operating lease assets | 312 | 269 | ||
| Paid in kind interest | 1,298 | - | ||
| Provision for inventory losses | 486 | 341 | ||
| Foreign currency adjustments | (146) | - | ||
| Loss on extinguishment of debt | - | 2,534 | ||
| Loss on disposal of fixed assets | 416 | 334 | ||
| Unrealized gain in marketable securities | (17) | 42 | ||
| Changes in: | ||||
| Inventory | 916 | (592) | ||
| Accounts receivable | (442) | (320) | ||
| Other current assets and prepaid expenses | 875 | 1,649 | ||
| Accounts payable | (125) | 314 | ||
| Accrued expenses | 357 | (5,812) | ||
| Operating lease liabilities | (265) | (319) | ||
| Net cash used in operating activities | $(13,198) | $(31,261) | ||
| Cash flows from investing activities | ||||
| Purchase of marketable securities | (4,012) | (30,878) | ||
| Proceeds from sale of marketable securities | 1,263 | 47,577 | ||
| Issue of/return of security deposits | - | 10 | ||
| Purchase of property and equipment | (478) | (4,385) | ||
| Net cash provided by (used in) investing activities | $(3,227) | $12,324 | ||
| Cash flows from financing activities | ||||
| Proceeds from issuance of common stock through at the market offerings | 8,135 | 642 | ||
| Proceeds from the sale of common stock of NeuroNos | 700 | - | ||
| Proceeds from issuance of common stock through exercise of warrants | 2,869 | - | ||
| Issuance of common stock warrants | 90 | - | ||
| Issuance of common stock and pre-funded warrants through securities purchase agreement II | - | 18,858 | ||
| Proceeds from long-term loan | 14,000 | 11,324 | ||
| Debt issuance costs | (996) | |||
| Payment of loans | (609) | (18,678) | ||
| Net cash provided by financing activities | $24,189 | $12,146 | ||
| Effect of exchange rate changes on cash and cash equivalents | 170 | 16 | ||
| Increase in cash, cash equivalents and restricted cash | $7,934 | $(6,776) | ||
| Cash, cash equivalents and restricted cash at beginning of period | 4,896 | 11,608 | ||
| Cash, cash equivalents and restricted cash at end of period | $12,830 | $4,833 | ||
| Supplemental disclosure of non-cash investing and financing activities | ||||
| Debt discount | $1,094 | $260 | ||
| End of term loan liability | $ | - | $(272) | |
| Warrant liability | $ | - | $(219) | |
| Derivative liability | $775 | $(1,314) | ||
| Right-of-use assets | $ | - | $(309) | |
| Operating lease liability | $ | - | $(309) | |
| Fixed assets included in accounts payable | $377 | $446 | ||
| Supplemental disclosure of cash flow items: | ||||
| Interest paid | $307 | $1,112 | ||
| Income taxes paid | $ | - | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.